Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23249982 | 0.86 | TP53 (0.44) | TP53THRBMAPTGPR119PRMT5 | |
| SCHEMBL2862442 | 0.85 | ALDH1A1 (0.60) | TP53THRBMAPTCHRM4ALDH1A1 | |
| SCHEMBL8478310 | 0.84 | GPR119 (0.57) | TP53GPR119CHRM4STSPRMT5 | |
| SCHEMBL20120662 | 0.84 | CHRM2 (0.46) | GPR119CHRM4STS | |
| SCHEMBL20120659 | 0.84 | CHRM2 (0.46) | GPR119CHRM4STS | |
| SCHEMBL23270010 | 0.82 | TP53 (0.53) | TP53THRBMAPTGPR119CHRM4 | |
| SCHEMBL8474293 | 0.82 | KDM4E (0.56) | TP53THRBMAPTGPR119CHRM4 | |
| SCHEMBL28868788 | 0.82 | BCHE (0.50) | STSPRMT5WDR77 | |
| SCHEMBL3570582 | 0.81 | ACHE (0.61) | TP53THRBMAPTGPR119CHRM4 | |
| SCHEMBL3406000 | 0.81 | CHRM4 (0.54) | CHRM4PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4041724-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| CN-114641473-A | BRD9 bifunctional degradation agent and use method thereof | 诺华股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| WO-2021055295-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055295-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | BRD9, BRD2, BRD1 | TP53 265/4885THRB 1172/4885MAPT 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.